PATH vs TSHA · P/E 19, rev $1.61B vs rev $8.3M
Uipath Inc (PATH) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported TSHA revenue for 2024-12-31 was $8.3M. Net income was -$89.3M. Revenue was down 46.1% from 2023-12-31 to 2024-12-31. TSHA currently screens at market cap $640.7M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the PATH and TSHA stock pages for the full models.
Not investment advice.